Randy Watts is the Chief Investment Strategist at William O’Neil + Co. Inc. With more than 25 years of equity asset management experience, Mr. Watts has a specific focus on large- and small-cap growth stocks. He started his career as an Equity Analyst at Freedom Capital Management in Boston, before spending nine years at Westfield Capital Management as an Equity Analyst and then as a Partner and Portfolio Manager overseeing a $500-plus million growth stock portfolio. While at The Boston Company, Mr. Watts was a Senior Managing Director with responsibility for small- and midcap growth investments. He managed $4 billion in long and long/short equity portfolios and hired, trained and managed a team of investment professionals.

In this exclusive interview with the Wall Street Transcript, Mr. Watts details his firm’s investing philosophy:  We “would say both as part of the William O’Neil philosophy and as part of my own personal philosophy in investing and in life, there’s nothing new under the sun. So one of the reasons this methodology works is because investors’ patterns of behavior repeat themselves over history. And in addition, innovations, new products, new industries, etc., those have always existed. There are always new products and new companies and new industries coming into being that offer great investment opportunities. And so I think by studying what’s worked in the past and then also trying to identify investments with those same kinds of catalysts and drivers today, I think that offers an attractive and profitable way to invest.”

In the full interview, Randy Watts details many stocks in the full interview.   “…One stock we find interesting that’s kind of fun to talk about is a U.S. restaurant company called Wingstop (NASDAQ:WING). They own and franchise cooked-to-order chicken wings. And they’ve got currently, I believe, 1,088 restaurants in eight countries. That includes 994 U.S.-based restaurants, of which 971 are franchised and 23 are company-owned. Outside the U.S., they have 94 franchised restaurants in seven countries.”

“The way their revenue currently breaks down is they get about 63% of their revenue from royalty revenue and franchise fees and about 37% of revenue from their own company-owned stores. They are more focused on takeout than dine-in, so most of their business is driven by take-away. They are, we think, one of the faster-growing restaurant brands in the United States. They have recently reported a quarter which we thought was strong. They had strong same-store sales that came in over 4%. They think, this year, that they’re going to be able to expand their units in the low teens, so kind of 13% to 15% with positive same-store sales and earnings growing north of 20%. So we think the earnings growth can be in the 20% to 25% range.”

Visit the Wall Street Transcript to read the complete interview.

Brian Boyle is the Founder, President and Chief Investment Officer of Boyle Capital. Mr. Boyle founded Boyle Capital in 2004, and as President and Chief Investment Officer, he is responsible for investment management and asset allocation at the firm. He graduated summa cum laude from the University of Northern Iowa with a bachelor’s in finance.  In this exclusive interview with the Wall Street Transcript, Mr. Boyle details some interesting guidance for the current market.

“Growth is enjoying the longest outperformance relative to value on record. The two longest periods before this were the late 1990s, early 2000s and the early 1970s. In both cases, the underperformance of value relative to growth corrected, and when it corrected, the correction was rather sharp. We are not predicting a major market correction, but it is important for investors to understand where they’re at in the cycle. And from where we sit, the growth over value is extremely long in the tooth.”

Brian Boyle does pick at least one sector to outperform in the next two years.  “Energy is one area we see value today as it is among the most hated sector and maybe the most hated it has ever been relative to the broader market. Within the energy sector, some of the areas that we find to be attractive would be more in the natural gas space. When we look at supply-and-demand fundamentals, we look at the third quarter as being kind of an important quarter for the overall energy markets.  The consensus has been for the last year and a half that prices are going to stay lower for longer and that there is an abundant amount of natural gas in the ground that can be accessed at almost any price. And yet, what we see is that supply growth, while it’s up a little year over year, has slowed considerably over the last couple of years to the point where the non-weather demand growth is now exceeding supply growth by quite a margin.”

To see specific names that Mr. Boyle has chosen, read the entire interview at the Wall Street Transcript.

Frederic G. Burke is the Senior Vice President and Manager of Sandy Spring Trust. Mr. Burke has over 25 years of extensive experience in fiduciary and asset management. Prior to joining Sandy Spring Trust, he served as President and Chief Investment Officer of Johnston Lemon Asset Management. Mr. Burke has published numerous articles and monthly essays on current fiduciary and investment issues, has been commended by the Washington Business Journal for “his level head and ability to avoid bubbles,” and continues to be interviewed by business publications regarding wealth management strategies.  Sandy Spring Trust is the fiduciary and investment entity of Sandy Spring Bank. Sandy Spring Trust has a long-established reputation for patience, consistency and skill in the management of investment and fiduciary relationships. We currently manage around $1.4 billion for trust, high net worth and not-for-profit organizations in the Washington, D.C. area.

Frederic Burke points out that the macro picture has many dark points but is overall bright.  “Rather than focusing on known risks with unknown outcomes, most markets appear to be focused on underlying fundamentals. New records are being set by stocks, investor sentiment is positive, and households’ exposure to equities is not at an extreme, all of which suggest that this market has some “legs.” Economic growth and consequently investment growth is an incredibly complex process. The current market will be followed by a bear market, and a significant tightening by the Fed will provide the signal.”

Mr. Burke reveals a large number of his top tier large cap portfolio picks, and has invested in money center banks at this point in the economic cycle.  “A good example of a large cap with a strong dividend policy which we favor is JPMorgan Chase (NYSE:JPM). They have a great franchise with a nimble management team. They have done a fantastic job of taking costs out and understand the implications of the regulatory environment. Johnson & Johnson (NYSE:JNJ) and Citigroup (NYSE:C) have similarly aggressive management teams.”

For more large cap recommendations from Frederic Burke, read the entire interview at the Wall Street Transcript.


Bobby Edgerton is a Co-Founder of the Capital Investment Companies, and has served as an Executive Officer of the companies since 1984. He is also the firm’s Chief Investment Officer and has been in the financial services industry since 1979. After winning the North Carolina State High School Golf Championship, Mr. Edgerton accepted both a basketball and golf scholarships from Wake Forest University and graduated with a B.A. in business and finance.  In  this exclusive interview with the Wall Street Transcript, Mr. Edgerton details his investment philosophy and top picks for his investors.

Mr. Edgerton has a multi-step discipline to choosing the stocks for his portfolio.  “The fifth part of the five-point program is the two ways you make money in the stock market. Number one is by buying good companies and never selling them, then you don’t pay any tax. That works fine in a lot of cases. I bought Apple in 1995 for me and my father’s profit-sharing plan at $36 a share. I bought 500 shares; it split two-for-one, so it went from 500 to 1,000, and then to 2,000, and then split seven-to-one, so it’s now 14,000 shares — $18,000 is worth over $2 million now. I’ve never sold a share, and this is in our retirement plan. Now, will I ever sell and diversify? Maybe.”

Some of the portfolio positions are under the radar of most professional money managers.  “Another stock that most people have never heard of is the monstrous FANUC, the symbol is FANUY. They are the largest maker of industrial robots in the world. They have $7 billion in cash, they have no debt, and they are a monster. I’m probably the only guy who buys stocks and in a sense hopes the stocks go down, because I want more shares. I guess my wish hasn’t been granted. FANUC has gone from $16 to $22…”

Overall, Bobby Edgerton concludes that “if you buy a good stock when it’s down and it goes up substantially over time, and during that time you have one stock that’s up and maybe two, three, four, five that are down, they are probably just as good a company, they’re just on a down cycle. You multiply one stock into three, five or six, and then you keep doing that over time, and the stock multiplies, kind of like a chain action in physics…I remember when Firestone back in 1975 had a tire called the 500 which went bad; Wall Street dumped the stock, which they are prone to do on any kind of bad news, and it was around $7. Nine years later, Bridgestone (OTCMKTS:BRDCY) bought Firestone at $80 a share. “

To get more of the Bobby Edgerton positions and their basis for purchase, read the entire interview at the Wall Street Transcript.

Matt Sweeney is the Managing Partner of Laughing Water Capital. Laughing Water Capital is a private investment fund formed in February of 2016 which employs a value-based strategy to identify mispriced securities for inclusion in a concentrated portfolio of eight to 20 investments that the Managing Partner believes provide the opportunity for anomalous returns over three-to-five-year periods. While the fund’s mandate allows it to seek long and short investments across geographies, market caps and capital structures, the fund primarily invests long in small and midcap U.S.-based equity securities that are off the radar of larger, less patient investors.  In this exclusive interview with the Wall Street Transcript, this highly regarded value investor discusses his recent top picks.

Matt Sweeney points out the key investing characteristic for his portfolio.  “We are looking for situations where over the next three to five years, something drastic is going to change, whether that be operational improvement at the company or a change in perception by the Street or some kind of combination of both of those factors.”  This strategy has yielded returns far above the market comparisons.

The stocks identified are far off the beaten path.  “An example of something that we would look at that is just off the beaten path for most investors would be Redknee Solutions (TSE:RKN), and it is a Canadian microcap stock. When you look at it on the surface, it basically has all of the things that Wall Street hates. It has some operational problems. In fact, a year ago, they ran into balance sheet problems and had to do some restructuring and then announced they were undergoing a strategic review. More recently, they completed a rights offering, whereby they raised money to fund a turnaround of the company.”

“We generally avoid turnarounds, but what I think is interesting in this case is that prior to the rights offering, when the company first announced that they were putting themselves up for a strategic review, there was a bidding process whereby two of the world’s best software investors essentially fought for the right to invest in this company.”

To get more insight into Matt Sweeney’s investment philosophy and details on more of his top picks, read the entire interview in the Wall Street Transcript.

McGavock Dunbar is a Principal and the Equity Analyst at Vulcan Value Partners. Mr. Dunbar joined Vulcan Value Partners in 2010.  Vulcan Value Partners was founded by C.T. Fitzpatrick in 2007 after he left Southeastern Asset Management in Memphis, where he served as a Portfolio Manager for 17 years. “We opened to outside investors in 2010, and that’s when I joined the firm. Today we manage over $14 billion across five strategies, with most of the capital in the Large Cap and the Small Cap strategy.”

In this exclusive interview with the Wall Street Transcript, McGavock Dunbar details his firm’s investing philosophy.  “We have just one guiding strategy, and that is to identify really high-quality businesses that have inherently stable values, and then wait for an opportunity to buy them at a discount to intrinsic value. We are value investors, but we don’t look for cheap stocks. Instead, we spend our time looking for good businesses with inherently stable values and follow them very closely. Then we wait for the market to give us the opportunity.”

The porfolio positions itself based on these relative value situations.  “We are constantly trying to minimize the weighted average price-to-value ratio of the portfolio. We are often trimming names with higher price to values and redeploying that capital into companies with lower price to values, all while maintaining a very high-quality bar.”

A few examples show the philosophy in action.  “So let’s use Boeing (NYSE:  BA) as an example. As one of the best performers in the S&P, we sold that position when we thought it reached our estimate of intrinsic value, and we’ve been allocating that capital to more discounted names with a greater margin of safety. Some examples of those are in U.S. drug distribution industry, including McKesson (NYSE:MCK)AmerisourceBergen (NYSE:ABC) and Cardinal Health (NYSE:CAH). The stock prices for these companies have not performed well. However, we think they are very good companies and competitively entrenched with stable intrinsic values.”

To see more of the portfolio’s top picks, read the entire interview at the Wall Street Transcript.

Michael Testorf, is the Managing Director and Portfolio Manager of ClearBridge Investments.  Mr. Testorf is a portfolio manager on the Global Growth Equity investment team and co-manages numerous global and international growth strategies. He joined ClearBridge Investments in 2015 and has 30 years of investment industry experience. Prior to joining ClearBridge, Mr. Testorf served as a senior portfolio manager and Senior Partner at R Squared Capital Management. For many years, he worked at Artio Global Management — formerly Julius Baer — where he was most recently a senior portfolio manager for international equities.

His funds follow a distinct philosophy.  “…We focus on high-quality companies that trade at a discount to their intrinsic value. You can even call it a valuation approach to growth. We take a deep dive into the fundamentals of a company and the sector in order to determine the upside. The degree of conviction and liquidity determines the position size within a portfolio, and we have a fairly concentrated portfolio, between 50 and 70 names. We are targeting good risk-adjusted returns. The turnover normally averages between 30% and 40% per year.”

The trades are unique and based on strong quantitative values.  “We are differentiated from other growth funds in two primary ways. One is how we define growth in three different categories that are normally mirroring the life cycle of a company. At the beginning is our emerging growth bucket. These are innovative and disruptive companies that have new business models and normally a very large addressable market. These companies grow very fast, but earnings are normally low because they put every single cent into the upcoming growth.

The second one, our largest and the one that brings the most performance to our overall portfolio, is the secular growth bucket. We consider these companies to have a superior business model, sustainable long-term growth opportunities and the ability to compound above-market returns year by year. Normally, this category gives us a good stability of returns in the portfolio.

Last is our structural growth bucket.”

Temenos, particularly here in the U.S., has just started to land its first big wins, and the pipeline is very, very promising…The company could ultimately go down two avenues: pursue strong growth opportunities, particularly in the U.S., or being open to be acquired by large software companies like Oracle (NYSE: ORCL) or SAP (NYSE: SAP). The current market capitalization of the company is palatable at $8 billion.”

To see more top picks from Micheal Testorf from ClearBridge and his investing rationale, read the entire interview at the Wall Street Transcript.

Omotayo Okusanya is a Managing Director in the equity research department at Jefferies & Company, Inc., and Senior Analyst responsible for coverage of real estate investment trusts — REITs. Prior to Jefferies, Mr. Okusanya was employed at UBS Securities LLC for seven years and was the lead analyst responsible for coverage of health care, biotech, self-storage and data center REITs.  His research has been recognized in annual analyst rankings published by The Wall Street Journal in 2008 as well as Forbes magazine in 2009 and 2010.

Mr. Okusanya has applied a very rigorous framework onto the various healthcare REITs, with a fair amount of pessimism in the sector.  One category that enjoys the Jefferies Managing Director’s favor are the medical office based real estate.  In the exclusive interview with the Wall Street Transcript he states that “…a fair amount of them are family or doctor practices, or internist-type practices. However, you also see a lot of specialists in medical office buildings as well. And one of the reasons why you’re seeing more and more specialists in medical office buildings is this push by the health care systems to move procedures into the cheapest-cost settings. And you very often find that a lot of procedures can be done on an outpatient basis in the medical office building rather than in the hospital.”

Some specific negative recommendations are also covered in the interview.  Mr. Okusanya states that “…on the skilled nursing side, our bigger concern is you may start to see tenant bankruptcies, and it’s going to drive valuation multiples lower for REITs with skilled nursing exposure. Uncertainty around health care reform and weak admission volumes also make it difficult to be bullish on hospitals.  So we would not advise investors be very active in the health care REIT area for the next six to 12 months.”

To get the specific picks and pans from the exclusive interview from the highly respected research Managing Director, read the entire report in the Wall Street Transcript.

Dana Hambly, CFA, is a Research Analyst covering health care services for Stephens Inc.  Prior to joining Stephens Inc., he was a Research Associate at Jefferies & Company, Inc., from 2006 to 2011, covering various health care sectors including health care services, health care IT and distribution.

A macro view informs Mr. Hambly’s observations in his exclusive interview with the Wall Street Transcript:  “…this year what has emerged starting at the hospital level has been a slowdown in volume growth. And it’s unclear what is driving that slowdown in volume growth. Is it an anomaly? Do we pick up next year? Or is it just a fundamental shift in the way health care services are being delivered? We’re not really sure. It’s unclear, and I think the uncertainty has really has put a lot of pressure, broadly speaking, on the health care services space.”

His wide view of the sector has several different foci, including health care related real estate investment trusts or REITs.  “Broadly speaking on the REIT side, I think the health care REITs relative to other REIT classes have been an outperformer for a number of years; however, as we look at assisted living, that industry has actually been under quite a bit of pressure over the last couple of years, and it’s mainly been about the pace of new supply. There’s been a lot of construction going on in assisted living, and that has challenged operators, particularly with their occupancy. And so occupancy has been declining in the assisted living sector for a few years now, And we think that will probably persist at least through the middle of 2018…”

An example of his top picks is The Ensign Group (NASDAQ:ENSG).  “We see Ensign as a very quality operator with a good balance sheet that will be able to prove quality and therefore take volume from its competitors. So we think they’re at the early stages of that dominance; they’re very acquisitive, and they tend to find underperforming facilities. They can buy them cheaply and then over a few years’ time grow them to where they’re very quality performers.”

To get further top picks from the Stephens Health Care Research Team, read the entire interview at the Wall Street Transcript.

Amin Omar is the Chief Operating Officer of Innovotech Inc. Dr. Omar is a biofilm expert, having completed his Ph.D. at Manchester University in England.  In this exclusive interview with the Wall Street Transcript, Dr. Omar  details how his company meets client needs through the provision of contract research services to a wide scope of companies, including oil and gas, pharmaceutical, consumer products and food processing. He also oversees the Research and Development Operations for Innovotech with regard to proprietary antimicrobial silver compounds.

He describes his recent strategic change for the company:  “In 2014, the board of directors decided on changing management, which resulted in a huge shift in the strategy that the company was pursuing. That year, I was promoted to General Manager, and I had to make some serious changes to the structure of the company in terms of which products we should pursue and which ones we should kill. We had to drop any products that burned cash and didn’t bring significant revenues, while we focused on the current departments that generate decent cash.”

The successful strategic shift has borne fruit.  “Between 2014 and now, the hard work paid off, and we managed to pay almost all legacy liabilities that were stifling us. We are focusing on expanding our contract research services, expanding our plate sales and finding the right partners to take our silver products to market.”

To get the details on the future prospects of Innovotech from Dr. Amin Omar, read the entire interview at the Wall Street Transcript.

« Previous PageNext Page »